Article first published online: 23 FEB 2012
Copyright © 2011 American Association for the Study of Liver Diseases
Volume 55, Issue 3, pages 749–758, March 2012
How to Cite
Zeuzem, S., Buggisch, P., Agarwal, K., Marcellin, P., Sereni, D., Klinker, H., Moreno, C., Zarski, J.-P., Horsmans, Y., Mo, H., Arterburn, S., Knox, S., Oldach, D., McHutchison, J. G., Manns, M. P. and Foster, G. R. (2012), The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology, 55: 749–758. doi: 10.1002/hep.24744
Potential conflict of interest: The authors disclose the following financial relationships. S.Z. has been a clinical investigator and/or consultant for Abbott Laboratories, Achillion Pharmaceuticals, Anadys Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, iTherX, Merck & Co., Novartis Pharmaceuticals, Pharmasset, Roche/Genentech, Santaris Pharma A/S, Tibotec Pharmaceuticals, Transgene, and Vertex Pharmaceuticals. P.B. has been a consultant and invited speaker for Janssen Pharmaceuticals, Roche, Schering-Plough Corporation, Merck & Co., Gilead Sciences, and Novartis Pharmaceuticals. K.A. has received grant support from Gilead Sciences, Roche, and Astellas Pharma and has been a consultant and speaker for Gilead Sciences, Merck Sharp & Dohme, Janssen Pharmaceuticals, Abbott Pharmaceuticals, GlaxoSmithKline, Roche, Astellas Pharma, Novartis Pharmaceuticals, and Bristol-Myers Squibb. P.M. has received grant support, served as a speaker, and/or participated as an investigator for Roche, Schering Plough, Gilead, Bristol-Myers Squibb, Vertex Pharmaceuticals, Novartis Pharmaceuticals, Pharmasset, Tibotec Pharmaceuticals, MSD, Boehringer Ingelheim, Abbott Laboratories, Pfizer, and Echosens. D.S. has been a clinical investigator for Gilead Sciences. H.K. has been a consultant for and/or received honoraria for speaking engagements from Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, Roche, and Tibotec Pharmaceuticals. C.M. has been a consultant for Janssen Pharmaceuticals, adviser for Janssen Pharmaceuticals and Merck Sharp & Dohme, speaker for Bristol-Myers Squibb, Janssen Pharmaceuticals, and Merck Sharp & Dohme, and received research grants from Roche and Merck Sharp & Dohme. J.-P.Z. has been a consultant and speaker for Merck & Co., Roche, Janssen Pharmaceuticals, Bristol-Myers Squibb, and Gilead Sciences. Y.H. has served as a consultant for Gilead Sciences, Roche, Merck & Co., Ipsen, Helsinn, and Johnson & Johnson Pharmaceuticals, a clinical investigator for Gilead Sciences, Novartis, Merck & Co., Tibotec Pharmaceuticals, Boehringer Ingelheim, Roche, and GlaxoSmithKline, and received grants from GlaxoSmithKline, Roche, Merck & Co., and AstraZeneca. M.P.M, has received grant support, consulting fees or honoraria, and support for travel from Merck & Co., consultant fees from Roche, Bristol-Myers Squibb, Gilead Sciences, Boehringer-Ingelheim, Novartis Pharmaceuticals, Tibotec Pharmaceuticals, Vertex Pharmaceuticals, GlaxoSmithKline, and Merck & Co., grants from Roche, Gilead Sciences, Novartis Pharmaceuticals, Boehringer-Ingelheim, Bristol-Myers Squibb, and Merck & Co., and payment for development of educational presentations from Merck & Co., Roche, Bristol-Myers Squibb, GlaxoSmithKline, and Gilead Sciences. G.F. has received personal and institutional funding from Gilead Sciences, Roche, Bristol-Myers Squibb, Merck & Co., Chugai Pharma, and GlaxoSmithKline. H.M., S.A., S.K., D.O., and J.G.M. are current or former employees of Gilead Sciences.
This trial was supported by Gilead Sciences.
- Issue published online: 23 FEB 2012
- Article first published online: 23 FEB 2012
- Accepted manuscript online: 17 OCT 2011 10:32AM EST
- Manuscript Accepted: 2 OCT 2011
- Manuscript Received: 9 AUG 2011
- 7Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716., , , , , , et al.
- 10Telaprevir in combination with peginterferon alfa-2a and ribavirin for 24 or 48 weeks in treatment-naïve genotype 1 HCV patients who achieved an extended rapid viral response: final results of the phase 3 ILLUMINATE Study. HEPATOLOGY 2010; 52( Suppl 1):Abstract LB-2., , , , , , et al.
- 19VX-222 with TVR alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: ZENITH study interim results. J Hepatol 2011; 54( Suppl 1): S540., , , , , , et al.
- 21Antiviral, pharmacokinetic, and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected subjects. HEPATOLOGY 2007; 46( Suppl 1): 255A., , , , , , et al.
- 22Dose-ranging, three-day monotherapy study of the HCV NS3 protease inhibitor GS-9256. J Hepatol 2010; 52( Suppl 1): S466-S467., , , , , , et al.
- 23A phase 2B trial comparing 24 to 48 weeks treatment with tegobuvir (GS-9190)/PEG/RBV to 48 weeks treatment with PEG-RBV for chronic genotype 1 HCV infection. J Hepatol 2011; 54( Suppl 1): S181., , , , , , et al.
- 26Mechanisms of isolated unconjugated hyperbilirubinemia induced by the HCV NS3/4A protease inhibitor BI201335. J Hepatol 2011; 54( Suppl 1): S488., , , , , , et al.
- 30Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders. J Hepatol 2011; 54( Suppl 1): 1356., , , , , , et al.
- 31Once daily dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV RNA < LOD at day 14: first purine/pyrimidine clinical combination data (the Nuclear study). J Hepatol 2011; 54( Suppl 1):Abstract LB-1370., , , , , , et al.